ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Sponsor: Eli Lilly and Company

Expanded Access
Approved for Marketing
Sponsor score: 60
Inactive

ClinicalTrials ID:NCT00040625

Patient View

This clinical trial evaluates the effects of ALIMTA, alone or with Cisplatin, on malignant pleural mesothelioma. Eligible participants include those with a confirmed diagnosis, not candidates for curative surgery, and with prior chemotherapy. Exclusions include recent investigational agent use, recent radiation, or eligibility for curative surgery. Participants must provide informed consent.

Patient Parameters

Program Overview

This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.

Eligibility Criteria

Inclusion Criteria

  • Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery
  • Prior chemotherapy for your disease is allowed
  • Measurable lesion is not required
  • Have a adequate performance status
  • Sign an informed consent form

Exclusion Criteria

  • You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study
  • You are excluded from this trial if you have received radiation within the previous 2 weeks
  • You are excluded from this trial if you are a candidates for curative surgery

Get This Program In Your Inbox

You can sign up and apply your patients for this program.